The integrity of the carboxyl-terminal BRCT repeat region is critical for BRCA1 tumor suppressor function; however, the molecular details of how a number of clinically derived BRCT missense mutations affect BRCA1 function remain largely unknown. Here we assess the structural response of the BRCT tandem repeat domain to a well characterized, cancer-associated single amino acid substitution, Met-1775 3 Arg-1775. The structure of BRCT-M1775R reveals that the mutated side chain is extruded from the protein hydrophobic core, thereby altering the protein surface. Charge-charge repulsion, rearrangement of the hydrophobic core, and disruption of the native hydrogen bonding network at the interface between the two BRCT repeats contribute to the conformational instability of BRCT-M1775R. Destabilization and global unfolding of the mutated BRCT domain at physiological temperatures explain the pleiotropic molecular and genetic defects associated with the BRCA1-M1775R protein.
The integrity of the carboxyl-terminal BRCT repeat region is critical for BRCA1 tumor suppressor function; however, the molecular details of how a number of clinically derived BRCT missense mutations affect BRCA1 function remain largely unknown. Here we assess the structural response of the BRCT tandem repeat domain to a well characterized, cancer-associated single amino acid substitution, Met-1775 3 Arg-1775. The structure of BRCT-M1775R reveals that the mutated side chain is extruded from the protein hydrophobic core, thereby altering the protein surface. Charge-charge repulsion, rearrangement of the hydrophobic core, and disruption of the native hydrogen bonding network at the interface between the two BRCT repeats contribute to the conformational instability of BRCT-M1775R. Destabilization and global unfolding of the mutated BRCT domain at physiological temperatures explain the pleiotropic molecular and genetic defects associated with the BRCA1-M1775R protein.
Germ line mutations within the breast and ovarian cancer susceptibility gene BRCA1 predispose carriers to early onset breast and ovarian cancer, and it is estimated that ϳ5-10% of all breast cancers are caused by inheritance of dominant disease genes (1) . Various lines of evidence suggest that the BRCA1 protein product is involved in the regulation of multiple nuclear functions including transcription, recombination, DNA repair, and checkpoint control (for reviews, see Refs. [2] [3] [4] . BRCA1 is an 1863-amino acid nuclear phosphoprotein that includes an amino-terminal RING finger domain and two tandem carboxyl-terminal repeats, termed the BRCT domain. The importance of the conserved RING and BRCT domains to the tumor suppressor function of BRCA1 is demonstrated by the fact that the majority of known cancer-causing BRCA1 mutations localize to these domains (5) (6) (7) (8) (9) .
The extreme carboxyl-terminal region of BRCA1 contains two ϳ90 -100 amino acid sequence repeats called BRCT 1 (BRCA1 carboxyl-terminal) repeats that are the prototypical members of a protein fold superfamily that includes many proteins associated with DNA repair (10 -12) . The recently determined x-ray crystal structures of the human (13) and rat (14) BRCA1 BRCT repeats provide a framework for the interpretation of BRCT mutations identified in patients from breast cancer screening programs. The two structurally similar BRCT repeats resemble the structures of the isolated BRCT domains from XRCC1 (15) and DNA ligase III (16) and are composed of a central four-stranded, parallel ␤-sheet flanked by a single ␣-helix on one side (␣2), with a pair of ␣-helices (␣1 and ␣3) and a short 3 10 -helix on the opposite side. The two repeats are connected by a relatively flexible linker and pack together in a specific, head-to-tail manner that is conserved not only between human and rat BRCA1 but also in the BRCT domain of the p53-interacting protein, 53BP1 (13, 14) . Several cancer-associated BRCT missense mutations (1, 6) have been characterized in functional detail. Two extensively studied variants, A1708E and M1775R, ablate double-strand break repair and transcription function of BRCA1 (17) (18) (19) and inhibit BRCT interactions with histone deacetylases (20) , the DNA helicase BACH1 (21) , and the transcriptional co-repressor CtIP (22, 23) . Both of these mutations occur at the interface between the amino-and carboxyl-terminal BRCT repeats and are predicted to affect the way in which the two repeats interact. The enhanced sensitivity of the A1708E mutant to proteolytic digestion indicates that this mutation has profound structural consequences (13) . In contrast, the M1775R mutant displays a proteolytic sensitivity that is intermediate between that of the wild type protein and the A1708E mutant, suggesting that the M1775R mutation results in a milder structural defect.
In the present study we employed limited proteolysis, CD spectroscopy, and x-ray structural analysis to probe the structural consequences of the M1775R mutation. Our results show that the methionine-arginine substitution leads to a rearrangement of the BRCT repeat interface, alterations in the surface of the protein, and global destabilization of the BRCT domain.
EXPERIMENTAL PROCEDURES
Proteolysis-For proteolytic assays, BRCT-WT and BRCT-M1775R were expressed from the T7 expression vector pLM1 and labeled with [ 35 S]methionine using the TNT-Quick in vitro transcription/translation system (Promega). Immediately before digestion, proteins were translated at 30°C for 2 h. The reticulocyte lysates were then centrifuged for 2 min at 10000 ϫ g to remove insoluble material; 3 l of the lysate supernatants containing the labeled translation products were added to 12 l of digestion buffer (150 mM NaCl, 50 mM potassium phosphate, pH Protein Expression and Purification-Expression and purification of recombinant human BRCA1-(1646 -1859) (BRCT-WT) and BRCA1-(1646 -1859)-M1775R (BRCT-M1775R) was performed essentially as described (13), with some changes. When expressed at 30 and 37°C, yields of BRCT-M1775R were greatly reduced relative to BRCT-WT, likely because of degradation. To obtain large quantities of BRCT-M1775R protein for crystallization studies, growth of cells and induction of protein expression were carried out at 25°C. Purification using a combination of ammonium sulfate precipitation, hydrophobic interaction, gel filtration, and anion exchange chromatography yielded 4 -5 mg of protein/liter Escherichia coli culture for both proteins. Matrixassisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometric analysis confirmed mutation of residue Met-1775 to arginine.
CD Spectroscopy-For circular dichroism measurements, proteins were dialyzed into 400 mM NaCl, 50 mM potassium phosphate (pH 7.5), 0.1% ␤-mercaptoethanol, in a Millipore Ultrafree-10 concentration unit. Protein concentrations for molar ellipticity calculations were derived from amino acid analysis. Far-UV (195-255 nm) CD spectra were determined using 0.2 mg/ml solutions of protein and were acquired using a Jasco J-720 spectrapolarimeter that was interfaced with Jasco software and equipped with a 0.1-cm quartz cuvette cell. For denaturation experiments, temperature within the cell was regulated using a Peltier thermal control unit. Assuming a two-state unfolding model, denaturation midpoints were determined by following the change in molar ellipticity at 222 nm as a function of temperature. Measurements were taken at 0.5°C intervals, and the temperature was increased at a rate of 30°C/h. Ellipticity readings were normalized to the mole fraction of protein folded (f f ) or denatured (f u ) using the standard equations
where [] n and [] u are the molar ellipticity for the fully folded and fully denatured protein species. [] is the observed ellipticity at each temperature. The midpoint of the temperature-dependent folding-unfolding transition for both proteins was reproducible, but this transition was irreversible and characterized by precipitation within the cell under the conditions used.
Crystallization of BRCT-M1775R-Protein concentrations for crystallization were determined using the BCA protein assay (Pierce). Unlike the wild type protein, storage of the mutant at concentrations greater than 5 mg/ml resulted in irreversible aggregation within days. To attain high protein concentrations suitable for crystallization, BRCT-M1775R at 1 mg/ml was dialyzed into Protein buffer (400 mM NaCl, 5 mM Tris-HCl, pH 7.5) and concentrated to 20 mg/ml immediately prior to crystallization. Crystals were grown at room temperature (20 -22°C) using the hanging drop vapor diffusion technique. 2 l of 20 mg/ml BRCT-M1775R in Protein buffer was mixed with 2 l of well solution (1.4 M ammonium sulfate, 100 mM MES, pH 6.7, 10 mM CoCl 2 ) to produce hexagonal crystals within 1 to 2 days (see Table I ).
Data Collection, Structure Solution, and Refinement-For data collection, crystals were gradually transferred to a cryoprotectant solution 
FIG. 2. Protease sensitivity of BRCT-M1775R.
A, reticulocyte lysates containing 35 S-labeled, in vitro-translated BRCT-WT and BRCT-M1775R were digested at the indicated temperatures for 12 min using chymotrypsin at concentrations of 0, 6, 60, 600 g/ml (lanes 1-4) . Reaction products were analyzed by SDS-PAGE and autoradiography. B, quantification of chymotryptic digestions. The fraction remaining is the percent of starting protein present following digestion with the indicated concentrations of chymotrypsin. Data points are the mean value of digestions performed in triplicate with error bars reflecting the S.D.
collected from a single crystal at 100 K at the Structural Biology Centre (Argonne National Laboratory)-APS beamline 19-ID. Intensity data were processed using the HKL2000 package (24) (see Table I ). Crystallographic phase information for BRCT-M1775R was obtained using molecular replacement with the native human BRCT model (RCSB, 1JNX) (13) . All data between 20 and 2.8 Å were used in crystallographic refinement, and 7% of this data was allocated for cross-validation. Initial rigid body fitting of the model in the Crystallography and NMR System (CNS) (25) (27, 28) . The quality of the model was assessed using PROCHECK (Ref. 29 , Table I ). The final model (see Table I ) has good stereochemistry and a working R-factor of 27.3% (R free , 29.8%) for all data in the resolution range 20 -2.8 Å. Structural diagrams were created using BOBSCRIPT (30) and rendered with POVRAY (www. povray.org) (Figs. 1, 4, and 5, A and B) or RASTER3D (31) (Fig. 5, C-E) . Molecular surfaces were drawn with GRASP (32).
RESULTS AND DISCUSSION
Native Packing Environment of Met-1775-The tandem BRCT repeat structure is composed of two ␣/␤-fold BRCT domains that interact end-to-end, with helices ␣1Ј and ␣3Ј from the carboxyl-terminal BRCT intimately contacting ␣2 from the amino-terminal repeat in a three-helix bundle-like packing arrangement (Fig. 1A) (13, 14) . Residue Met-1775 is largely buried within the interface between the two repeats and lies in a pocket formed by Leu-1701 and Phe-1704 from the amino-terminal repeat and Leu-1780, Met-1783, Arg-1835, and Leu-1839 from the carboxyl-terminal repeat. Sequence and structural conservation of Met-1775 and its contacting residues among mammalian, xenopus, and avian BRCA1 homologues highlights the importance of Met-1775 in orienting the two BRCT repeats (Fig. 1B) (13, 14) . With the exception of residue Arg-1835, which is replaced by a tryptophan in the mouse and rat BRCT domains, the residues forming this pocket are highly conserved. This substitution within the pocket is significant, however, as proximity of the positively charged residue Arg-1835 to Met-1775 in the human protein influences the response of the structure to the 
cancer-linked substitution, M1775R.
Proteolytic Sensitivity of M1775R-Mutant M1775R conferred moderate sensitivity to digestion with trypsin at 20°C (13) . Because Arg-1775 immediately precedes a proline residue, this substitution is not expected to introduce a new trypsin cleavage site; thus the enhanced trypsin sensitivity is an indication of a subtle structural change in the M1775R mutant. To further assess the stability of the M1775R mutant, we compared its chymotrypsin sensitivity to that of the wild-type protein (Fig. 2, A and B) . BRCT-WT and BRCT-M1775R both show resistance to digestion at 20°C for all protease concentrations. Elevating the temperature to 37°C enhanced cleavage of the mutant by chymotrypsin at all protease concentrations, whereas the wild type showed only a slight increase in cleavage efficiency at the highest concentration. The fact that the BRCT-M1775R exhibits modest but significant increases in sensitivity to digestion by two proteases with different cleavage specificities, especially at elevated temperatures, indicates that M1775R results in a folding defect in the BRCT domain.
CD Analysis-To further probe the extent of protein destabilization induced by the M1775R substitution, we compared the secondary structure and thermal stability of BRCT-M1775R to the wild type protein using CD spectroscopy ( b R sym ϭ 100 3). The mutant exhibits a far-UV CD absorbance spectrum that is characteristic of a mixed ␣/␤ protein and is similar to the wild type, indicating that the overall fold of the M1775R domain is maintained in solution at 20°C. BRCT-M1775R, however, is less stable, having a midpoint of thermal denaturation of ϳ41°C, 11°C less than the wild type protein (see Fig. 3 , inset and "Experimental Procedures"). Consistent with these findings, solvent denaturation measurements of the thermodynamic stability of the BRCT tandem domain indicates that M1775R destabilizes the BRCT fold by 5.0 kcal/mol at 20°C (36) . Taken together, these results suggest that functional defects associated with BRCA1-M1775R may be attributed to destabilization of the BRCT domain at physiological temperatures. X-ray Structure of Missense Variant M1775R-To gain structural insights into the destabilizing effect of M1775R, we crystallized and determined the structure of BRCT-M1775R at 2.8 Å (see Fig. 4A , Table I , and "Experimental Procedures"). 2F o ϪF c and F o ϪF c difference electron density indicate that structural rearrangements in response to the mutation are confined to residues within an ϳ5 Å radius of Arg-1775. Paired 4-positive and -negative electron density features in the F o ϪF c map near residue 1775 reveal that the substituted arginine is displaced from the hydrophobic core of the protein (Fig. 4A) . The mutation is further accommodated by an ϳ1 Å shift of a neighboring residue, Pro-1776, in the ␤1Ј-␣1Ј connecting loop and a series of side chain rearrangements that perturb the native inter-BRCT hydrogen bonding and van der Waals contact networks (Fig. 5, A-C) .
Introduction of an arginine at position 1775 creates a clustering of three positively charged residues, Arg-1699, -1775, and -1835. In the native structure, Arg-1699 from the aminoterminal BRCT repeat participates in the sole conserved inter-BRCT repeat salt bridge with a pair of carboxyl-terminal BRCT acidic residues, Asp-1840 and Glu-1836 (Fig. 5A) . Arg-1835 in human BRCA1 normally participates in a hydrogen bonding network with Gln-1811, thereby helping to orient the ␤1Ј-␣1Ј loop (Fig. 5A) . The positively charged guanidinium group of variant Arg-1775 is found positioned between two large positive peaks in our electron density maps that we have interpreted to be sulfate molecules, the highest concentration anion in the crystallization mother liquor (Figs. 4 and 5B). In the mutant, Arg-1699 retains the salt bridge with Asp-1840 but no longer contacts Glu-1836 and instead coordinates an anion. Arg-1835 rotates away from Gln-1811 and forms a new salt bridge with Glu-1836. Thus, it appears that electrostatic stabilization of this positive charge cluster is achieved through ordering of solvent anions and a cascade of hydrogen bonding alterations.
The adjustments in the positions of Arg-1775 and -1835 described above result in the displacement of the aliphatic portions of these side chains from the protein core (Fig. 5C) . In response to these movements, Leu-1780 shifts to maintain van der Waals contact with the arginine residues. These movements are accomplished without the creation of large, energetically costly cavities within the hydrophobic core (33) (34) (35) . The repacking of the core, however, in combination with instability created by hydrogen bonding changes and charge-charge repulsion of basic residues at the BRCT-BRCT interface may collectively help account for the 5 kcal/mol destabilization reported for the BRCT-M1775R protein (36) .
Few crystallographic examples documenting protein structural responses to the introduction of charged residues into the hydrophobic core are available. Structural investigation of a comparable, highly destabilizing mutation in T4 lysozyme, Met-102 3 Lys-102, reveals the position of the lysine side chain changes little when compared with native Met-102 packing (37) . Instead, the mutation is accompanied by increased mobility of flanking residues, including a helix that normally packs against the substituted methionine. This motion allows access of the buried, basic side chain to solvent via a folding-unfolding transition of neighboring structured regions. The structural rearrangement that we observe in BRCT-M1775R is less dramatic but nevertheless results in the expulsion of the charged side chain from the hydrophobic protein core.
Destabilization of the BRCT Abrogates BRCA1-M1775R Function-At the surface of the protein, a hydrophobic groove near Met-1775 is apparent in the wild type structure (Fig. 5D) . With the movement of Arg-1775 in the mutant, this cleft becomes occluded with charged atoms (Fig. 5E) . This raises the possibility that, in addition to the destabilizing effect of the mutation, the substitution may disrupt association of BRCA1 with its interaction partners by directly modifying an exposed protein binding site. However, this site does not overlap with a BACH1 binding site that maps to the ␤3-␣2 connecting loop (Fig. 1) of the amino-terminal BRCT repeat (14) , which is greater than 20 Å away from Met-1775. BACH1 binding is impaired by the M1775R substitution, suggesting that global structural defects resulting from the mutation, rather than localized structural and electrostatic perturbation, are responsible for the binding defect. Moreover, variant M1775R is defective in many biochemical assays that assess BRCA1 function and is unable to interact with several other proteins that associate with the wild type BRCT domain (Table II) . It is unlikely that all of these proteins target a common surface near Met-1775 that is changed by the mutation. We therefore suggest that the wide spectrum of molecular defects reported for variant M1775R is explained by the destabilization of the domain.
Measurement of the steady state levels of BRCA1 missense variants M1775R, P1749R, and A1708E reveals they are similar to the wild type, suggesting that these proteins are not destabilized to the degree that they are degraded significantly in vivo (17, 23) . Although it is difficult to predict individual energetic contributions of the M1775R rearrangements to BRCT destabilization, it is clear that the cumulative changes affecting the structure across the BRCT-BRCT interface result in a temperature-sensitive tandem BRCT domain (Figs. 2 and  3 ) that is defective in BRCA1 protein interaction, transcription, and DNA repair functions. In analogous studies, the quantitative measurement of the thermodynamic stability of the p53 tumor suppressor has shown that many of the common cancercausing mutations are destabilizing. Consequently, p53 is inactivated by mutation, and cell cycle control is lost (38) . Because many of the BRCT missense variants destabilize the BRCT to the same extent or more than M1775R (13, 36), 2 we might expect these variants to possess molecular and disease phenotypes similar to M1775R. Examination of the effects of other missense mutations on BRCA1 cellular function will be necessary to correlate BRCT loss of structure with BRCA1 loss of function and will further establish protein misfolding as a basic molecular mechanism of disease.
